“We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase ... at the 2024 EORTC-NCI-AACR 36 th Symposium on Molecular Targets ...

Research has shown that certain molecular components, such as extracellular signal ... The goal was to observe whether these ...

Cash Position: Cash, cash equivalents, and marketable securities were $463.3 million as of September 30, 2024, compared to $322.0 million as of December 31, 2023. Erasca expects its current cash, cash ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today announced its launch with a $101 million Series ...

BURLINGAME, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update ...

Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously ... as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

Amyotrophic lateral sclerosis (ALS) is the most common form of MND and there is currently no cure for ... Pietro Fratta, ...

which tells us that they are not only easy to form but also that they're very resilient to destruction. That stability, ...